Approach to venous thromboembolism in the cancer patient.
Venous thromboembolism (VTE) is frequently encountered in cancer patients, acts as an important cause of morbidity and mortality, and may be a predictor of worse prognosis. In cancer patient who have a poor life expectancy, preventing death from pulmonary embolism is the mainstay of treatment. Patients who present with severe hypotension or other clinical manifestations suggestive of critical pulmonary embolism and do not have contraindications to thrombolysis should promptly be administered thrombolytic drugs. Except for selected cases requiring aggressive therapy, treatment of VTE in patients with cancer should not differ from that of patients without malignancy; the initial treatment should be conducted with adjusted dose of unfractionated heparin (UH), fixed dose of low-molecular-weight heparins (LMWH), or fondaparinux. LMWHs and fondaparinux have the potential to greatly simplify the initial treatment of VTE, making the management of the pathology feasible in an outpatient setting for selected patients. Traditionally, in cancer as well as in non-cancer patients, UH or LMWH or fondaparinux are overlapped by oral anticoagulation, targeted to reach an International Normalized Ratio (INR) between 2.0 and 3.0, and then followed by oral anticoagulants. However, during oral anticoagulant therapy, cancer patients exhibit a two- to fourfold higher risk of recurrent VTE and major bleeding complications when compared to non-cancer patients. Studies performed during the current decade have demonstrated that LMWHs offer several advantages in terms of efficacy in preventing VTE recurrences without increasing the bleeding risk. According to International Guidelines, the long-term administration of LMWH should be considered an alternative to anti-vitamin K drugs in patients with advanced disease and in those with conditions limiting the use of oral anticoagulants. The targeted policy is to administer LMWH at full therapeutic doses for the first month of treatment and then 75% of the initial dose for at least the following 5 months of therapy. Prolongation of anticoagulation should be considered for as long as the malignant disorder is active. In patients with acute deep venous thrombosis and contraindications to anticoagulation, vena cava filters should be considered. If anticoagulation is temporarily contraindicated, retrievable filters should be considered. Only patients who are actively bleeding or who are at extremely high risk for bleeding should receive a filter without anticoagulation coverage.
Department of Cardiothoracic and Vascular Sciences, Thromboembolic Unit, University Hospital of Padova, Padova, Italy, andreapiccioli@libero.it.
Andrea
A
Piccioli
Paolo
P
Prandoni
N Engl J Med. 2009 Dec 10;361(24):2342-52
19966341
Ann Oncol. 2005 May;16 Suppl 4:iv136-139
15923414
Semin Thromb Hemost. 2003 Dec;29 Suppl 1:3-8
14730471
Lancet Oncol. 2005 Jun;6(6):401-10
15925818
Ann Intern Med. 1996 Jul 1;125(1):1-7
8644983
Ann Oncol. 2010 May;21 Suppl 5:v274-6
20555096
Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001100
15495007
Expert Opin Pharmacother. 2010 Aug;11(12):2049-58
20642371
Oncologist. 2003;8(4):381-8
12897335
N Engl J Med. 2003 Oct 30;349(18):1695-702
14585937
JAMA. 2005 Feb 9;293(6):715-22
15701913
Br J Cancer. 2010 Apr 13;102 Suppl 1:S17-23
20386545
Ann Intern Med. 2004 Jun 1;140(11):867-73
15172900
Blood. 2002 Nov 15;100(10):3484-8
12393647
J Thromb Haemost. 2009 May;7(5):760-5
19245418
N Engl J Med. 2003 Jul 10;349(2):146-53
12853587
Circulation. 2005 Jul 19;112(3):416-22
16009794
J Clin Oncol. 2007 Dec 1;25(34):5490-505
17968019
Haematologica. 1999 May;84(5):437-45
10329923
N Engl J Med. 2010 Dec 23;363(26):2499-510
21128814
Haematologica. 2005 Feb;90(2):220-4
15710575
J Thromb Haemost. 2009 Jul;7 Suppl 1:322-7
19630826
J Clin Oncol. 2000 Sep;18(17):3078-83
10963635
Thromb Haemost. 2009 Apr;101(4):762-9
19350123
Br J Cancer. 2010 Apr 13;102 Suppl 1:S2-9
20386546
Chest. 2008 Jun;133(6 Suppl):454S-545S
18574272
Ann Intern Med. 2001 Feb 6;134(3):191-202
11177331
N Engl J Med. 2001 Mar 1;344(9):626-31
11228276
Blood. 2005 Dec 15;106(13):4027-33
16076870
Intern Emerg Med. 2010 Oct;5 Suppl 1:S27-30
20865471
Cancer. 2008 Oct 1;113(7):1685-94
18720360
Arch Intern Med. 2002 Aug 12-26;162(15):1729-35
12153376
Am J Med. 2006 Dec;119(12):1062-72
17145251